PCSK9 and acute coronary syndrome: Two monoclonal antibodies against PCSK9, evolocumab and alirocumab reduce LDL cholesterol by 50–70% and have shown major reductions in cardiovascular events in high-risk patients, including within 12 months of acute coronary syndromes.52, 53, 54 Inclisiran, a small molecule based PCSK-9 inhibitor has also shown efficacy in reducing LDL cholesterol and effectiveness in reducing cardiovascular outcomes in CAD.55